Trial Profile
Multicentric, Prospective Open-label Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With Atypical Hemolytic Uremic Syndrome (aHUS)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Atypical Haemolytic Uraemic Syndrome
- Focus Therapeutic Use
- Acronyms STOPECU
- 03 Dec 2020 Results published in the Blood
- 05 Dec 2019 Status changed from active, no longer recruiting to completed.
- 21 Nov 2017 Status changed from recruiting to active, no longer recruiting.